DeCode's new offering adds to an ongoing controversy over whether people in the island country have a right to know if they are at increased risk for disease.
Applicants will be expected to develop the capacity to conduct up to 200,000 genome-wide assays per year and generate high-quality genotyping and genome sequence data.
The prospective analysis suggests that the approach could help clinicians identify patients at risk of a stroke who could benefit from anticoagulant treatment.
